---
audienceLevel: patient
cancerTypes:
- breast
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Trastuzumab and Hyaluronidase-oysk - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/trastuzumabandhyaluronidase-oysk
version: v1
---

# Trastuzumab and Hyaluronidase-oysk - NCI

# Trastuzumab and Hyaluronidase-oysk

Placeholder slot

(tras-TOO-zoo-mab â€¦ HY-al-yoo-RAH-nih-days)

Trastuzumab and hyaluronidase-oysk consists of a combination of the monoclonal antibody trastuzumab and a recombinant enzyme called hyaluronidase-oysk, which allows trastuzumab to more easily enter tissues. Trastuzumab binds to HER2, a protein found in high levels on some cancer cells and causes them to grow. This binding blocks the ability of HER2-positive cancer cells to send chemical signals that tell them to grow. It also stimulates the immune system to kill cells that have a lot of HER2. Trastuzumab and hyaluronidase-oysk is a type of targeted therapy drug.

US Brand Name(s)

Herceptin Hylecta

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebf30894-41cf-480c-8bc3-56f592a13813)

## Use in Cancer

Trastuzumab and hyaluronidase-oysk
is approved to treat:

- **[Breast cancer](/Common/PopUps/popDefinition.aspx?id=444971&version=Patient&language=English)** that is [HER2 positive](/Common/PopUps/popDefinition.aspx?id=737998&version=Patient&language=English) (HER2+). It is used in adults with:
- [Hormone receptor-negative](/Common/PopUps/popDefinition.aspx?id=788033&version=Patient&language=English) or [high-risk](/Common/PopUps/popDefinition.aspx?id=45079&version=Patient&language=English) cancer. It is given:
- as [combination chemotherapy](/Common/PopUps/popDefinition.aspx?id=45650&version=Patient&language=English) with:
- [doxorubicin](/Common/PopUps/popDefinition.aspx?id=560140&version=Patient&language=English), [cyclophosphamide](/Common/PopUps/popDefinition.aspx?id=45253&version=Patient&language=English), and either [paclitaxel](/Common/PopUps/popDefinition.aspx?id=45258&version=Patient&language=English) or [docetaxel](/Common/PopUps/popDefinition.aspx?id=45382&version=Patient&language=English); or
- docetaxel and [carboplatin](/Common/PopUps/popDefinition.aspx?id=45182&version=Patient&language=English)
- alone after combination therapy that included [anthracycline](/Common/PopUps/popDefinition.aspx?id=44916&version=Patient&language=English) chemotherapy
- [Metastatic](/Common/PopUps/popDefinition.aspx?id=44058&version=Patient&language=English) cancer. It is given:
- with paclitaxel for [first-line treatment](/Common/PopUps/popDefinition.aspx?id=346494&version=Patient&language=English); or
- alone in patients who have already been treated with at least one chemotherapy [regimen](/Common/PopUps/popDefinition.aspx?id=45864&version=Patient&language=English) given for metastatic cancer

Trastuzumab and hyaluronidase-oysk
is a form of trastuzumab that is given as a [subcutaneous](/Common/PopUps/popDefinition.aspx?id=45914&version=Patient&language=English) [injection](/Common/PopUps/popDefinition.aspx?id=44678&version=Patient&language=English). This form can be given in less time than trastuzumab, which is given as an [infusion](/Common/PopUps/popDefinition.aspx?id=45738&version=Patient&language=English). For more information about trastuzumab that may apply to trastuzumab and hyaluronidase-oysk, see the Drug Information Summary for [Trastuzumab](/about-cancer/treatment/drugs/trastuzumab).

## More About Trastuzumab and Hyaluronidase-oysk

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/797111) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Trastuzumab and Hyaluronidase-oysk](https://medlineplus.gov/druginfo/meds/a619041.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Trastuzumab And Hyaluronidase-oysk](https://www.cancer.gov/research/participate/clinical-trials/intervention/C158060) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
